Legal & General Group
NBSE

Legal & General Group’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Legal & General Group’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-99
Closed -$15K – 3686
2021
Q1 		$15K Sell
99
-10
-9% -$1.81K ﹤0.01% 3261
2020
Q4 		$15K Hold
109
– – ﹤0.01% 3204
2020
Q3 		$16K Sell
109
-33
-23% -$5.38K ﹤0.01% 3056
2020
Q2 		$25K Buy
+142
New +$23.8K ﹤0.01% 2974

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Legal & General Group's NBSE Position: Q2 2021 in Review

Legal & General Group sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2021, closing a stake of 99 shares — an estimated $15K sold.

Legal & General Group first reported a position in NBSE in Q2 2020 and held it in 4 quarters. The position peaked at $25K in Q2 2020. 57 funds tracked by Wall St. Rank hold NBSE as of Q2 2021.

  • Legal & General Group reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 99 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $15K.
  • Legal & General Group first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q2 2020 and held it in 4 quarters.
  • Legal & General Group's NeuBase Therapeutics, Inc. Common Stock position peaked at $25K in Q2 2020.
  • 57 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.